Voyager Therapeutics (NASDAQ:VYGR) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research report sent to investors on Monday morning,Benzinga reports. They currently have a $30.00 target price on the stock.

Several other equities research analysts also recently weighed in on the company. Cantor Fitzgerald began coverage on Voyager Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating and a $5.73 price target on the stock. Citigroup began coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 target price for the company. Canaccord Genuity Group restated a “buy” rating and issued a $14.00 price target on shares of Voyager Therapeutics in a report on Thursday, November 14th. Wedbush started coverage on shares of Voyager Therapeutics in a report on Friday, November 29th. They set an “outperform” rating and a $11.00 price objective for the company. Finally, Leerink Partners began coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price on the stock. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $15.97.

Voyager Therapeutics Stock Up 0.2 %

Shares of VYGR opened at $5.63 on Monday. The business has a fifty day moving average of $5.81 and a 200 day moving average of $6.60. The company has a market cap of $307.57 million, a PE ratio of 7.93 and a beta of 0.93. Voyager Therapeutics has a 52-week low of $4.99 and a 52-week high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The firm had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. During the same quarter last year, the business earned ($0.59) EPS. As a group, research analysts anticipate that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the transaction, the chief operating officer now directly owns 112,328 shares in the company, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders sold 10,778 shares of company stock valued at $58,548 over the last 90 days. Corporate insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

A number of institutional investors have recently added to or reduced their stakes in VYGR. Erste Asset Management GmbH purchased a new stake in shares of Voyager Therapeutics during the third quarter valued at about $6,192,000. Barclays PLC lifted its position in Voyager Therapeutics by 55.8% during the third quarter. Barclays PLC now owns 104,462 shares of the company’s stock valued at $612,000 after acquiring an additional 37,398 shares during the last quarter. Verition Fund Management LLC acquired a new stake in Voyager Therapeutics in the third quarter valued at approximately $216,000. Massachusetts Financial Services Co. MA grew its holdings in Voyager Therapeutics by 19.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 171,856 shares of the company’s stock worth $1,005,000 after purchasing an additional 28,333 shares during the last quarter. Finally, FMR LLC increased its position in shares of Voyager Therapeutics by 26.9% during the third quarter. FMR LLC now owns 92,498 shares of the company’s stock worth $541,000 after purchasing an additional 19,622 shares in the last quarter. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.